Influence of Hemodialysis on Lipid Peroxidation, Enzymatic and Non-Enzymatic Antioxidant Capacity in Chronic Renal Failure Patients

Zargari, Mehryar; Sedighi, Omid

doi:10.5812/numonthly.28526

Cited by 25 publications

(27 citation statements)

References 27 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased oxidative stress is a critical accompaniment in HD patients, since they live with uremic toxins, are regularly exposed to dialyzer membranes and receive a different rate of dialysis blood flow during HD treatment . A strategy may very well be warranted for HD patients to either decrease their oxidative stress or increase their antioxidant capacities in order to keep the balance of oxidative stress and antioxidant capacities.…”

Section: Discussioncontrasting

confidence: 62%

“…The progression of chronic kidney disease (CKD) to the advanced stage generates an excessive amount of reactive oxygen species, which contributes to the eventual development of the end stage of renal disease, such as what occurs in haemodialysis (HD) patients, who are in a pro‐oxidant state . Although malondialdehyde (MDA) is a water‐soluble product of lipid peroxidation with a low molecular weight, and can be theoretically removed through HD treatment, increased lipid peroxidation after HD treatment has been reported in previous studies . If patients receiving HD treatment are potentially at increased oxidative stress, adequate antioxidant capacities to prevent cells from sustaining oxidative damage are of paramount importance for HD patients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Higher glutathione demand may be necessary for assisting haemodialysis patients to cope with increased oxidative stress

et al. 2019

View full text Add to dashboard Cite

Aim The removal of cysteine during a dialysis procedure may affect glutathione (GSH) concentration, allowing haemodialysis (HD) patients to become more susceptible to oxidative damage. This study was performed to determine whether the change of GSH/glutathione disulfide (GSSG) redox state and GSH redox potential were linked with the change of cysteine or oxidative stress in patients receiving HD treatment. Methods Sixty‐seven HD patients who had received regular HD treatment were recruited. Plasma GSH, GSSG, cysteine and malondialdehyde (MDA) were measured at both pre‐ and post‐HD. Results Plasma cysteine, GSH and GSSG levels significantly decreased after the completion of HD, compared to the levels at pre‐HD. Plasma MDA concentration, GSH/GSSG ratio and GSH redox potential remained constant during the dialysis session. Plasma GSH and GSSG were positively associated with plasma MDA at post‐HD, while GSH redox potential was negatively associated with plasma MDA at post‐HD. However, plasma GSH, GSSG, GSH/GSSG ratio and GSH redox potential were not associated with plasma cysteine at either pre‐ or post‐HD. Conclusion The GSH and GSSG levels were significantly utilized during a HD session, and their levels were significantly associated with increased oxidative stress. HD patients may require higher GSH demands to cope with increased oxidative stress during an HD session.

show abstract

Section: Discussioncontrasting

confidence: 62%

mentioning

confidence: 99%

Higher glutathione demand may be necessary for assisting haemodialysis patients to cope with increased oxidative stress

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Previous studies have revealed a significant imbalance of pro-oxidants and antioxidants in patients with CKD and diabetes [15,16,19,24,25]. It is also well known that bilirubin shows an antioxidant capacity, as in neonatal patients with increased bilirubin levels [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

“…The level of TAC was estimated in all these 30 samples. Low TAC was also provided from chronic kidney failure patients after a renal replacement treatment session [16].…”

Section: Patientsmentioning

confidence: 99%

Establishing reference values and evaluation of an in-house ferric reducing antioxidant power (FRAP) colorimetric assay in microplates

Üstündağ¹,

Huysal²,

Kahvecioğlu³

et al. 2016

Eur Res J

View full text Add to dashboard Cite

Objectives. The total antioxidant capacity (TAC) of a sample can be measured with a ferric reducing antioxidant power (FRAP) assay. There are commercially available kits for FRAP assays, however they are more expensive than in-house kits. We aimed to evaluate a FRAP direct measurement method under our laboratory conditions using a microplate reader and establish reference values to use in future research projects. Methods. An inhouse microplate adaptation of the FRAP method was evaluated. Reference values of FRAP were established for one hundred and twenty subjects aged between 25-55 years. FRAP levels were estimated in 30 serum samples with high glucose concentration, 44 hyperbiluribinemic neonatals and 16 patients receiving renal replacement therapy (RRT). Results. The mean FRAP level was 890±235 µmol/L. The median TAC level was 904 µmol/L. This method was found to be linear up to at least 2000 µmol/L. The intra-and inter-assay coefficients of variation were 2.7-6.7% and 5.3-10.1%, respectively. The mean FRAP level was lower than normal in diabetes and RRT patients and higher in hyperbiluribinemic neonatals (687±209 µmol/L, 609±250 µmol/L and 945±187 µmol/L, respectively). Conclusions. Our reference values give comparable results with the literature. This method is simple, reliable, and inexpensive. It could be used for studies of oxidative stressrelated diseases.Eur Res J 2016;2(2):126-131

show abstract

“…The relationship between cancer and free radicals has been studied (3,4). Antioxidant compounds have been shown to slow down the development of chemically induced tumors (5)(6)(7)(8). It has been estimated that the most of human cancer cases are due to environmental factors and would be preventable if the main risks could be identified (9,10).…”

Section: Introductionmentioning

confidence: 99%

Synthesis of Vitamin E Novel Analogues as Anti-Cancer Compounds

Hosseini

Jalili

2016

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

Background: Antioxidant compounds have been shown to slow down the development of chemically induced tumors. It has been estimated that most of human cancer cases are due to environmental factors and would be preventable if the main risks could be identified. The potential of vitamin E as a cancer preventive agent has been studied and individuals whose intake of vitamin E was above average showed a low risk of lung cancer. Vitamin E is a mixture of four lipid soluble phenols including α-, β-, γ-, and δ-tocopherol. Objectives: In our study, to investigate the antioxidant activity of α-tocopherol-derived radicals in comparison with other phenoxyl radicals, a number of substituted phenols were synthesized, most of which contained t-butyl groups in the 2-and 6-positions. Materials and Methods: All the synthesized compounds were recrystallized and the nuclear magnetic resonance (NMR) spectra were run on Bruker GRYOSPES WM 360 machine; the IR spectra were also run on a Perkin Elmer 1430 ratio recording infrared spectrophotometer. Microanalyses were carried out on a Perkin Elmer 4000 CHN analyzer; all the melting points were measured by an electrothermal melting point apparatus, which were uncorrected. Results: Five synthesized vitamin E analogues, including

show abstract

Influence of Hemodialysis on Lipid Peroxidation, Enzymatic and Non-Enzymatic Antioxidant Capacity in Chronic Renal Failure Patients

Cited by 25 publications

References 27 publications

Higher glutathione demand may be necessary for assisting haemodialysis patients to cope with increased oxidative stress

Higher glutathione demand may be necessary for assisting haemodialysis patients to cope with increased oxidative stress

Establishing reference values and evaluation of an in-house ferric reducing antioxidant power (FRAP) colorimetric assay in microplates

Synthesis of Vitamin E Novel Analogues as Anti-Cancer Compounds

Contact Info

Product

Resources

About